Biovaxys Technology Corp (CSE:BIOV)

2025 Corporate Review

December 31, 2025

BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

December 17, 2025

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or...

Via Newsfile

BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D

December 15, 2025

Topics Intellectual Property

BioVaxys Technology Corp. Closes Debt Settlement Transaction

November 25, 2025

BioVaxys Technology Corp. Closes Listed Issuer Financing Exemption (LIFE) Private Placement

November 19, 2025

InvestorNewsBreaks – BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB), SpayVac-for-Wildlife Inc. Expand License Agreement

Topics Intellectual Property

April 22, 2025

Via Investor Brand Network

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

September 20, 2024

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024

September 17, 2024

BioVaxys invites individual and institutional investors, as well as advisors and analysts, to attend online at www.VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

September 16, 2024

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

The Power Play by The Market Herald Releases New Interviews with Reunion Gold Corp, Numinus Wellness, Core Assets, Blockmate Ventures, BioVaxys Tech, Carlyle Commodities and Belmont Resources Discussing Their Latest News

April 18, 2023

The Power Play by The Market Herald Releases New Interviews with Spey Resources, Melkior Resources and BioVaxys Technology Discussing Their Latest News

March 16, 2023

The Power Play by The Market Herald Releases New Interviews with ApartmentLove, Sirios Resources, Aton Resources, Mountain Boy Minerals and BioVaxys Technology Discussing Their Latest News

December 20, 2022

BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine

December 01, 2022

Vancouver, BC – December 1, 2022 – BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or “Company”) is pleased to announce the successful sterile and bacteria-free test-run...

EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END

Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope

December 01, 2022

The Power Play by The Market Herald Releases New Interviews with RDARS, Infinity Stone Ventures, BioVaxys Technology, and Sitka Gold Discussing Their Latest News

Topics Intellectual Property

October 06, 2022

Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing...

Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027

October 06, 2022

BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps

October 06, 2022

Agreement Includes Right of First Refusal in the US for Ovosicare and Libicare Vancourver, BC – October 6, 2022 – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or...

The Power Play by The Market Herald Releases a New Interview with BioVaxys Technology Discussing Their Latest News

September 28, 2022

Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression

May 18, 2022

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30...

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

Topics Death

May 18, 2022

Vancouver, BC – May 18, 2022 — BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or “Company”), announced today that Hospices Civils de Lyon, France (“HCL”) has agreed to...

Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer...

Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating

April 25, 2022

BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction

Topics Intellectual Property

April 25, 2022

Vancouver, BC – April 25, 2022 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has entered into an agreement with the Deaconess Research...

The Power Play by The Market Herald Releases Interviews With Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton Minerals, SWMBRD Sports, and BioVaxys Technology Corp.

Topics Economy

March 30, 2022

VANCOUVER, BC / ACCESSWIRE / March 30, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton...

From The Market Herald

Via AccessWire

Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players

March 24, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2022 – USA News Group – Whenever a new COVID-19 variant emergences, health authorities have had limited options to fight...

FN Media Group Presents USA News Group News Commentary Vancouver, BC – December 7, 2021 – USA News Group – Despite a level of panic that JP Morgan has already downplayed in its 2022 forecasts, the...

Biotech Sector’s Response to Omicron Panic Should be Swift and Effective

December 07, 2021

Palm Beach, FL – December 7, 2021 – FinancialNewsMedia.com News Commentary There are many unknowns surrounding the new omicron Covid variant; there are early signs it’s more transmissible, but it’s not...

Anxious World Waits As Covid Vaccine Makers Address Omicron Variant

December 07, 2021

FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 9, 2021 – USA News Group – New at-home Covid tests are on the way, according to the Biden administration, which announced...

Covid-19 Test Shortage Emphasized by New $70M Plan to Speed Up Authorizations

November 09, 2021

Palm Beach, FL – November 9, 2021 – FinancialNewsMedia.com News Commentary – The increasing outbreak of covid-19 is increasing the demand for coronavirus vaccines or therapies, which will result in the...

Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030

November 09, 2021

BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH

Topics Death

November 09, 2021

VANCOUVER, BC – November 9, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that results from its in vivo animal research study support...